Exhibit 99.1
Semler Scientific Reports Fourth Quarter and Full Year 2023 Financial Results
2023 Q4 and full year highlights compared to the corresponding period of 2022:
Santa Clara, CA – March 5, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.
“We are pleased to report continued growth in year-over-year quarterly and full year revenues and net income, predominately from sales of QuantaFlo® for peripheral arterial disease testing,” said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. “We remain focused on continuing to market our product while seeking a new 510(k) clearance from the FDA with expanded labeling for use as an aid in the diagnosis of other cardiovascular diseases.”
For the year ended December 31, 2023, compared to the corresponding period of 2022, Semler Scientific reported:
| ● | Revenues of $68.2 million, an increase of $11.5 million, or 20%, compared to $56.7 million. |
| o | Fixed fee software license revenues of $37.3 million, an increase of $3.3 million, or 9%, compared to $34.0 million. |
| o | Variable fee software license revenues of $29.0 million, an increase of $7.7 million, or 36%, compared to $21.3 million. |
| o | Sales of other products of $1.9 million, an increase of $0.5 million, or 42%, compared to $1.4 million. |
| ● | Cost of revenues of $7.0 million, an increase of $2.7 million or 64% compared to $4.3 million. As a percentage of revenues, cost of revenues increased to 10%, compared to 8% in the prior year period. |
| ● | Total operating expenses of $45.9 million, which includes cost of revenues, an increase of $6.4 million, or 16%, compared to $39.5 million. As a percentage of revenues, operating expenses decreased to 67% compared to 70%. |
| ● | Pre-tax income of $24.1 million, an increase of $6.4 million, or 36%, compared to $17.7 million. |
| ● | Income tax expense of $3.5 million, or an effective tax rate of 15%, compared to $3.4 million, or an effective tax rate of 19%. |
| ● | Net income of $20.6 million, or $3.06 per basic share and $2.63 per diluted share, an increase of $6.3 million, or 44%, compared to $14.3 million, or $2.13 per basic share and $1.79 per diluted share. |
Note: Cost of revenues for the full year ended December 31, 2023 includes a $2.5 million write-off of prepaid software licenses for Insulin Insights.
1
Semler Scientific’s two largest customers (including their affiliates) comprised 36% and 35% of full year revenues in 2023 and 40.4% and 29.0% of annual revenues in 2022.
For the fourth quarter ended December 31, 2023, compared to the corresponding period of 2022, Semler Scientific reported:
| ● | Revenues of $15.1 million, an increase of $1.3 million, or 9%, compared to $13.8 million. |
| o | Fixed fee software license revenues of $8.8 million, a decrease of $0.2 million, or 2%, compared to $9.0 million. |
| o | Variable fee software license revenues of $5.8 million, an increase of $1.3 million, or 28% compared to $4.5 million. |
| o | Sales of other products of $0.5 million, an increase of $0.2 million, or 71%, compared to $0.3 million. |
| ● | Cost of revenues of $3.4 million, an increase of $2.2 million, or 186%, compared to $1.2 million. As a percentage of revenues, cost of revenues was 22% compared to 9%. |
| ● | Total operating expenses of $12.5 million, which includes cost of revenues, an increase of $2.3 million, or 23%, compared to $10.2 million. As a percentage of revenues, operating expenses increased to 83%, compared to 74%. |
| ● | Pre-tax income of $2.8 million, a decrease of $1.2 million, or 29%, compared to $4.0 million. |
| ● | Income tax benefit of $1.4 million, or an effective tax benefit rate of 50% compared to income tax expense of $0.7 million, or an effective tax rate of 19%. |
| ● | Net income of $4.2 million, or $0.62 per basic share and $0.55 per diluted share, an increase of $1.0 million, or 31%, compared to $3.2 million, or $0.48 per basic share and $0.41 per diluted share. |
Note: Cost of revenues for the fourth quarter and full year ended December 31, 2023 includes a $2.5 million write-off of prepaid software licenses for Insulin Insights.
Semler Scientific’s three largest customers (including their affiliates) comprised 37%, 32% and 11% of the fourth quarter revenues in 2023 and two largest customers (including their affiliates) comprised 43.3% and 25.8% of fourth quarter revenues in 2022.
MAJOR ACCOMPLISHMENTS IN 2023
| 1. | Continued year-over-year revenue growth. |
| 2. | Continued year-over-year net income growth. |
| 3. | Record balance of cash and cash equivalents. |
Notice of Conference Call
Semler Scientific will host a conference call today at 4:30 p.m. ET. The call will address results of the fourth quarter and year ended December 31, 2023, as well as provide a business update on Semler Scientific’s strategies for the near-term future.
Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10185342/fb4eeec618. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:
2
Domestic callers: (833) 816-1161
International callers: (412) 317-0717
Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific’s website at www.semlerscientific.com.
3
Semler Scientific, Inc.
Statements of Income
Unaudited
(In thousands of U.S. Dollars, except share and per share data)
| | For the three months ended December 31, | | For the year ended December 31, | ||||||||
|
| 2023 | | 2022 |
| 2023 |
| | 2022 | |||
| | | | | | | | | | | | |
Revenues | | $ | 15,056 | | $ | 13,794 | | $ | 68,184 | | $ | 56,686 |
Operating expenses: | | | | | | | |
| | |
| |
Cost of revenues | | | 3,384 | | | 1,182 | |
| 6,984 | |
| 4,252 |
Engineering and product development | | | 1,207 | | | 1,365 | |
| 5,773 | |
| 4,809 |
Sales and marketing | | | 4,546 | | | 4,654 | |
| 18,147 | |
| 17,685 |
General and administrative | | | 3,262 | | | 2,977 | |
| 14,290 | |
| 12,737 |
Strategic streamlining | | | 135 | | | — | | | 734 | | | — |
Total operating expenses | | | 12,534 | | | 10,178 | |
| 45,928 | |
| 39,483 |
Income from operations | | | 2,522 | | | 3,616 | |
| 22,256 | |
| 17,203 |
Interest and dividend income | | | 699 | | | 343 | |
| 2,471 | |
| 494 |
Impairment of investments | | | (337) | | | — | | | (337) | | | — |
Change in fair value of notes held for investment | |
| (90) | |
| — | |
| (307) | |
| — |
Other income (expenses) | | | 20 | | | (3) | | | 17 | | | (5) |
Other income, net | | | 292 | | | 340 | |
| 1,844 | |
| 489 |
Pre-tax income | | | 2,814 | | | 3,956 | | | 24,100 | | | 17,692 |
Income tax provision | | | (1,407) | | | 740 | |
| 3,517 | |
| 3,367 |
Net income | | $ | 4,221 | | $ | 3,216 | | $ | 20,583 | | $ | 14,325 |
Net income per share, basic | | $ | 0.62 | | $ | 0.48 | | $ | 3.06 | | $ | 2.13 |
Weighted average number of shares used in computing basic net income per share | | | 6,804,998 | | | 6,691,406 | |
| 6,732,806 | |
| 6,726,687 |
Net income per share, diluted | | $ | 0.55 | | $ | 0.41 | | $ | 2.63 | | $ | 1.79 |
Weighted average number of shares used in computing diluted net income per share | | | 7,734,263 | | | 7,917,991 | | | 7,819,159 | | | 7,999,750 |
4
Semler Scientific, Inc.
Balance Sheets
Unaudited
(In thousands of U.S. Dollars, except share and per share data)
| | December 31, | | December 31, | ||
| | 2023 |
| 2022 | ||
| | | | | | |
Assets | | | | | | |
Current Assets: | | | |
| |
|
Cash and cash equivalents | | $ | 57,200 | | $ | 23,014 |
Restricted cash | | | 132 | | | — |
Short-term investments | | | — | | | 20,073 |
Trade accounts receivable, net of allowance for credit losses of $287 and $109, respectively | |
| 6,125 | |
| 3,884 |
Inventory, net | | | 445 | | | 469 |
Prepaid expenses and other current assets | |
| 2,042 | |
| 1,468 |
Total current assets | |
| 65,944 | |
| 48,908 |
Assets for lease, net | |
| 2,285 | |
| 2,478 |
Property and equipment, net | |
| 720 | |
| 667 |
Long-term investments | |
| 512 | |
| 821 |
Notes held for investment (includes measured at fair value of $4,372 and $3,679, respectively) | | | 5,372 | | | 4,679 |
Other non-current assets | | | 270 | | | 2,842 |
Deferred tax assets | | | 2,962 | | | 2,298 |
Total assets | | $ | 78,065 | | $ | 62,693 |
| | | | | | |
Liabilities and Stockholders’ Equity | |
| | |
| |
Current liabilities: | | | | | | |
Accounts payable | | $ | 402 | | $ | 835 |
Accrued expenses | |
| 4,502 | |
| 4,748 |
Deferred revenue | |
| 1,120 | |
| 1,160 |
Other short-term liabilities | | | 176 | | | 114 |
Total current liabilities | |
| 6,200 | |
| 6,857 |
| | | | | | |
Long-term liabilities: | |
|
| |
|
|
Other long-term liabilities | | | 70 | | | 160 |
Total long-term liabilities | |
| 70 | |
| 160 |
Commitments and contingencies (Note 13) | | | | | | |
Stockholders’ equity: | |
| | |
| |
Common stock, $0.001 par value; 50,000,000 shares authorized; 7,099,441 and 6,906,544 shares issued, and 6,885,019 and 6,692,122 shares outstanding (treasury shares of 214,422 and 214,422), respectively | |
| 7 | |
| 7 |
Additional paid-in capital | |
| 11,985 | |
| 16,449 |
Retained earnings | |
| 59,803 | |
| 39,220 |
| | | | | | |
Total stockholders’ equity | |
| 71,795 | |
| 55,676 |
| | | | | | |
Total liabilities and stockholders’ equity | | $ | 78,065 | | $ | 62,693 |
5
Semler Scientific, Inc.
Statements of Cash Flows
Unaudited
(In thousands of U.S. Dollars)
| | Year ended December 31, | ||||
|
| 2023 |
| 2022 | ||
CASH FLOWS FROM OPERATING ACTIVITIES: | | | | | | |
Net income | | $ | 20,583 | | $ | 14,325 |
| | | | | | |
Reconciliation of Net Income to Net Cash Provided by Operating Activities: | |
| | |
|
|
Depreciation | |
| 599 | |
| 589 |
Deferred tax expense | | | (664) | | | (351) |
Loss on disposal of assets for lease | |
| 369 | |
| 463 |
Write off of prepaid software licenses | | | 2,476 | | | — |
Gain on short-term investments | | | (151) | | | (77) |
Allowance for credit losses | |
| 268 | |
| 103 |
Change in fair value of notes held for investment | | | 307 | | | — |
Stock-based compensation | |
| 944 | |
| 741 |
Impairment of long term investments | | | 337 | | | — |
Changes in Operating Assets and Liabilities: | |
| | |
| |
Trade accounts receivable | |
| (2,508) | |
| (367) |
Inventory | | | 24 | | | 81 |
Prepaid expenses and other current assets | |
| (603) | |
| 2,576 |
Other non-current assets | | | 96 | | | (2,510) |
Accounts payable | |
| (433) | |
| 392 |
Accrued expenses | |
| (246) | |
| 1,310 |
Other current and non-current liabilities | | | (68) | | | 188 |
Net Cash Provided by Operating Activities | |
| 21,330 | |
| 17,463 |
| | | | | | |
CASH FLOWS FROM INVESTING ACTIVITIES: | | | | | | |
Additions to property and equipment | |
| (345) | |
| (476) |
Purchase of notes held for investment | | | (1,000) | | | — |
Proceeds from maturities of short-term investments | | | 78,093 | | | (4,679) |
Purchase of short-term investments | | | (57,869) | | | (19,996) |
Purchase of assets for lease | |
| (483) | |
| (1,684) |
Net Cash Provided by (Used in) Investing Activities | |
| 18,396 | |
| (26,835) |
| |
| | |
| |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
|
| |
|
|
Taxes paid related to net settlement of equity awards | | | (3,510) | | | (114) |
Common stock warrants acquired | | | (1,949) | | | — |
Treasury stock acquired | | | — | | | (4,991) |
Proceeds from exercise of stock options | |
| 51 | |
| 168 |
Net Cash Used in Financing Activities | |
| (5,408) | |
| (4,937) |
INCREASE (DECREASE) IN CASH | |
| 34,318 | |
| (14,309) |
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | |
| 23,014 | |
| 37,323 |
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD | | $ | 57,332 | | $ | 23,014 |
Supplemental Disclosure of Cash Flow Information: | | | | | | |
Cash paid for taxes | | $ | 4,060 | | $ | 2,400 |
| | | | | | |
6
About Semler Scientific, Inc.:
Semler Scientific, Inc. develops, manufactures and markets innovative products and services that assist in evaluating and treating chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo® test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded indications. QuantaFlo® is used by healthcare providers to evaluate their patient’s risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific has a minority investment in Mellitus, SYNAPS Dx, as well as Monarch Medical Technologies LLC, a privately held company whose product EndoTool® offers a technological solution for inpatient glycemic management. Additional information about Semler Scientific can be found at www.semlerscientific.com.
Forward-Looking Statements
This press release contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words “believe,” “goal,” “may,” “will,” “intend,” “expect,” “anticipate,” “estimate,” “project,” “would,” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding seeking a new 510(k) clearance for QuantaFlo® with expanded indications for use; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific’s actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will continue to license its cardiovascular testing products, including the risk of changes in the reimbursement landscape for its customers including related to the recent CMS rate announcement; whether or not QuantaFlo® can successfully aid in the diagnosis of PAD or obtain a new 510(k) clearance for expanded indications; along with those risk factors detailed in Semler Scientific’s filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.
INVESTOR CONTACT:
Renae Cormier
Chief Financial Officer
ir@semlerscientific.com
SOURCE: Semler Scientific, Inc.
7